The document summarizes a team's final project presentation for a medical device startup called MammOptics. The team includes four members with engineering and business backgrounds working to develop a non-invasive, non-radiative breast cancer detection technology using optical spectroscopy. The presentation covers the initial technology and business model hypotheses, testing the value proposition with hospitals and doctors, and outlines the steps needed for product development, clinical trials, reimbursement, and company financing.
Aqua Partners LLC is a global life science consulting firm that has been operating since 1983. They help life science companies access technology, products, partnerships, and capital worldwide. Their team of professionals have expertise in areas such as M&A, strategic partnerships, licensing, clinical development, and venture investing. Aqua Partners provides strategic advisory, valuation, business development, market research, and M&A services to clients in the life science industry globally.
Four s fortnightly pharma health track 23th january - 5th febuary 2012Four-S
The document is a newsletter on the Indian healthcare industry from Four-S Services covering the period of January 23rd to February 5th, 2011. It discusses positive quarterly results for major healthcare companies in India with 28% year-over-year revenue growth. It also summarizes Dr. Reddy's Laboratories quarterly results with an 87.8% increase in net profit. The newsletter provides updates on private equity investment activity, mergers and acquisitions, regulatory news, and upcoming events in the healthcare sector.
Osage University Partners has had a productive fall, completing seven new investments in 2021 and bringing their portfolio to 16 companies. Their sector diversification strategy provided stability during difficulties in the life science and cleantech sectors. They remain cautiously optimistic for 2012 despite expecting a modest year. Their most recent investments include companies developing clinical trial software, intravenous access systems, preterm birth diagnostics, and oncology therapies targeting protein degradation pathways.
Fisher Scientific is a leading provider of products and services to the scientific community. In 2005, Fisher had revenues of $5.6 billion and approximately 19,500 employees worldwide. Fisher facilitates scientific discovery by supplying researchers and clinicians with the tools they need to enhance and prolong life. Key accomplishments in 2005 included strategic acquisitions that expanded Fisher's offerings in areas like biopharma services and life sciences, as well as operational initiatives that increased cost savings and production capabilities. Fisher is well-positioned for continued growth by meeting the evolving needs of customers in research, healthcare, and drug development.
Fisher Scientific is a leading provider of products and services to scientific researchers around the world. In 2005, Fisher had revenues of $5.6 billion and approximately 19,500 employees worldwide. The company facilitates scientific discovery by supplying researchers with over 600,000 products and services. Fisher aims to make its 350,000 customers more efficient and effective through its integrated supply chain and sales/marketing capabilities.
According to the website Investopedia, venture capital is a kind of private equity funding that is given by investors to new enterprises and small businesses that the investors feel have the potential for long-term development. In general, it is derived from wealthy investors, investment banks, and many other financial entities.
Transcell Biolife is a biobanking company founded by Dr. S Dravida to realize her vision of facilitating next-generation medicine. The company started in 2011 with its first product, ScellCare, a stem cell storage service, and has since expanded its offerings. Transcell Biolife aims to become a leading Asian biobank through organic growth and partnerships. Its stored biosamples and data will enable applications in areas like personalized medicine, clinical trials, and drug discovery. Under Dr. Dravida's leadership, the company is well-positioned to realize its goal of becoming the largest global biobank facilitating novel therapies.
The document summarizes a team's final project presentation for a medical device startup called MammOptics. The team includes four members with engineering and business backgrounds working to develop a non-invasive, non-radiative breast cancer detection technology using optical spectroscopy. The presentation covers the initial technology and business model hypotheses, testing the value proposition with hospitals and doctors, and outlines the steps needed for product development, clinical trials, reimbursement, and company financing.
Aqua Partners LLC is a global life science consulting firm that has been operating since 1983. They help life science companies access technology, products, partnerships, and capital worldwide. Their team of professionals have expertise in areas such as M&A, strategic partnerships, licensing, clinical development, and venture investing. Aqua Partners provides strategic advisory, valuation, business development, market research, and M&A services to clients in the life science industry globally.
Four s fortnightly pharma health track 23th january - 5th febuary 2012Four-S
The document is a newsletter on the Indian healthcare industry from Four-S Services covering the period of January 23rd to February 5th, 2011. It discusses positive quarterly results for major healthcare companies in India with 28% year-over-year revenue growth. It also summarizes Dr. Reddy's Laboratories quarterly results with an 87.8% increase in net profit. The newsletter provides updates on private equity investment activity, mergers and acquisitions, regulatory news, and upcoming events in the healthcare sector.
Osage University Partners has had a productive fall, completing seven new investments in 2021 and bringing their portfolio to 16 companies. Their sector diversification strategy provided stability during difficulties in the life science and cleantech sectors. They remain cautiously optimistic for 2012 despite expecting a modest year. Their most recent investments include companies developing clinical trial software, intravenous access systems, preterm birth diagnostics, and oncology therapies targeting protein degradation pathways.
Fisher Scientific is a leading provider of products and services to the scientific community. In 2005, Fisher had revenues of $5.6 billion and approximately 19,500 employees worldwide. Fisher facilitates scientific discovery by supplying researchers and clinicians with the tools they need to enhance and prolong life. Key accomplishments in 2005 included strategic acquisitions that expanded Fisher's offerings in areas like biopharma services and life sciences, as well as operational initiatives that increased cost savings and production capabilities. Fisher is well-positioned for continued growth by meeting the evolving needs of customers in research, healthcare, and drug development.
Fisher Scientific is a leading provider of products and services to scientific researchers around the world. In 2005, Fisher had revenues of $5.6 billion and approximately 19,500 employees worldwide. The company facilitates scientific discovery by supplying researchers with over 600,000 products and services. Fisher aims to make its 350,000 customers more efficient and effective through its integrated supply chain and sales/marketing capabilities.
According to the website Investopedia, venture capital is a kind of private equity funding that is given by investors to new enterprises and small businesses that the investors feel have the potential for long-term development. In general, it is derived from wealthy investors, investment banks, and many other financial entities.
Transcell Biolife is a biobanking company founded by Dr. S Dravida to realize her vision of facilitating next-generation medicine. The company started in 2011 with its first product, ScellCare, a stem cell storage service, and has since expanded its offerings. Transcell Biolife aims to become a leading Asian biobank through organic growth and partnerships. Its stored biosamples and data will enable applications in areas like personalized medicine, clinical trials, and drug discovery. Under Dr. Dravida's leadership, the company is well-positioned to realize its goal of becoming the largest global biobank facilitating novel therapies.
LifeCell International - PR WEEK Awards 2009Saurabh Rai
Hanmer MS&L received an award for their 2009 marketing campaign promoting LifeCell International and stem cell technology. The campaign was successful in positioning LifeCell as the preferred brand for stem cell banking and services in India, helping increase their sales by 60% over the previous year. Through educational, experiential, and media programs, the campaign generated significant awareness and visibility for LifeCell as a pioneer in the stem cell industry.
10 Most Innovative CRO’s To Watch In 2022.pdfinsightscare
During the COVID-19 pandemic, if clinicians, healthcare service-providing staff, nurses, and doctors were battling at the forefront, then the Clinical Research Organizations (CROs) have been working hard
Top 10 companies using CRISPR technologyARUNPANDIAN07
The revolutionary gene editing tool CRISPR/Cas9 has reached its height because of its accuracy and easy-to-design. Several gene corrections have been made by scientists in vitro and in vivo.
For more information, visit, www.theblackchalk.com
Katalyst Securities is a private equity/venture investment bank that specializes in growth capital and expansion stage investments in technology and healthcare. They source investment opportunities through a global network and partner with venture capital firms. Their goal is to identify innovative ideas, help bring them to life, create brands with long-term value, and drive successful results for portfolio companies and investors. They focus on transactions like private placements, alternative public offerings, and venture capital. Katalyst aims to achieve return on investment for entrepreneurs, high net worth individuals, family offices, and Swiss banks.
The New Orleans BioInnovation Center is a $48 million facility that partners with LSUHSC and Tulane to support the commercialization of biotechnologies in the region. It provides lab space, funding assistance, and business programming to 50 technology companies. Examples include NuMe Health, which is developing prebiotics for health conditions, and MiniVax, which received an NIH grant for vaccine development. The Center aims to continue growing the entrepreneurial culture and research base in the region while addressing challenges around workforce, capital, and retaining startup companies.
1) Evozyne uses evolution-based design and machine learning to engineer novel proteins to solve challenges in therapeutics and sustainability.
2) They have partnered with Takeda to develop an enzyme to treat a genetic disease, exceeding expectations, and are developing platforms for antibodies, gene editing, and gene optimization.
3) Evozyne aims to bring biology-based solutions to issues like carbon capture and untreated diseases by designing proteins with advanced functionality inspired by natural evolution.
Mc carter enabling innovation washu 11.7.14James McCarter
The Washington University Monsanto Graduate Fellows' Symposium on November 7th, 2014 fostered interaction between academia, industry, & entrepreneurship. Jim McCarter, Senior EIR at BioGenerator & Adjunct Professor of Genetics provided a quick tour of resources for start-ups at WashU & in St. Louis.
wyeth Download Documentation Credit Suisse Group Healthcare Conferencefinance12
This document is a presentation by Michael Kamarck from Wyeth discussing the company's manufacturing capabilities and strategies. It summarizes that Wyeth has a diversified business across pharmaceuticals, biotechnology, vaccines, and other areas. It has made over $3.5 billion in investments to support its biomanufacturing network and developed platform technologies to standardize processes. This allows production of multiple pipeline and commercial products using consistent materials and equipment. Wyeth has demonstrated the ability to increase yields and capacity for products like Enbrel and Prevnar through technological advances.
wyeth Credit Suisse Group Healthcare Conferencefinance12
This document provides an overview of Wyeth's business, including its diversification across scientific platforms, business platforms, and therapeutic approaches. It discusses Wyeth's core biotech/vaccine franchises that have high growth potential, such as Enbrel and Prevnar. The document also summarizes Wyeth's investments in biomanufacturing infrastructure and its leadership in biotech manufacturing and process development. Wyeth's standardized technology platforms are highlighted as helping to improve existing products and drive efficiencies.
The 10 most trusted vaccine solution providers, 2020Merry D'souza
In this edition, ‘The 10 Most Trusted Vaccine Solution Providers, 2020’ CIO Look has shortlisted various healthcare organizations which are playing an important role towards the global healthcare system.
This is a conference about drug discovery and drug development. G protein-coupled receptor (GPCR) and protein kinases are the biggest drug targets in medicine. Around half of all drugs, for whatever disease, work by interacting with different GPCRs and kinases.
Growing Stronger Research Fund Overview Jan 2012 For DonorsAmer Haider
Growing Stronger Research Fund aims to accelerate medical research to improve quality of life for people with Achondroplasia, the most common form of dwarfism. Their goal is to eliminate the need for multiple orthopedic surgeries by developing drug therapies. They are currently funding four research strategies, including blocking expression of the mutant gene or disabling the mutant protein. Their next steps are to raise $600,000 over three years to support additional lab testing and advance promising strategies toward clinical trials and approval.
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
The Southern California Consortium for Technology and Innovation in Pediatrics (CTIP) is one of seven FDA-funded pediatric device consortia working to develop medical devices for children. CTIP engages clinicians, engineers, entrepreneurs and others in developing pediatric technologies through events like Med-Innovation Rounds and symposiums. They provide support to 35 distinct pediatric device projects in their first year. To convince industry partners of opportunities in pediatrics, CTIP clearly defines projects' value propositions and market potential through due diligence. Their strategy pairs entrepreneurs with domain experts to advance technologies for children.
This document provides an overview of Kuwait Life Sciences Company (KLSC) and its subsidiaries which were established to stimulate the life sciences sector in the Middle East and North Africa region. KLSC is fully owned by NTEC, the technology transfer arm of the Kuwait Investment Authority. It has established five platform companies focused on pharmaceutical commercialization, medical devices, clinical research, healthcare training, and active pharmaceutical ingredients. The platforms work with world-class partners and have expanded operations across the MENA region since 2010. KLSC also invests in healthcare and life sciences funds and companies internationally.
The healthcare industry is being disrupted by technology and a shift to greater patient / individual empowerment. This represents a formidable opportunity for healthcare in Asia. What catalyst role could / should strategics play in Asia healthcare innovation and how?
The most advanced ivf and fertility centres 2018insightscare
With the need for high standards of IVF treatment, we bring the “The 10 Most Advanced IVF and Fertility Centers 2018.” These fertility clinics are providing contemporary paraphernalia to meet all the demands the IVF and Fertility vertical poses.
Biocat coordinates and promotes the biotechnology sector in Catalonia, focusing on adding value to research and consolidating biotechnology as an economic sector. BioWin is the health cluster of Wallonia that aims to foster innovation, human capital, infrastructure, and international promotion of SMEs. Euromediag stimulates synergy in the medical diagnostics sector in southern France through its network of over 70 partners from education, research, industry, healthcare, and government. LifeScience Klaster Krakow's medical diagnostics working group involves 27 organizations in research, services, and promotion related to molecular diagnostics, imaging, and biomarkers.
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
More Related Content
Similar to Osage University Partners Newsletter: December 2011
LifeCell International - PR WEEK Awards 2009Saurabh Rai
Hanmer MS&L received an award for their 2009 marketing campaign promoting LifeCell International and stem cell technology. The campaign was successful in positioning LifeCell as the preferred brand for stem cell banking and services in India, helping increase their sales by 60% over the previous year. Through educational, experiential, and media programs, the campaign generated significant awareness and visibility for LifeCell as a pioneer in the stem cell industry.
10 Most Innovative CRO’s To Watch In 2022.pdfinsightscare
During the COVID-19 pandemic, if clinicians, healthcare service-providing staff, nurses, and doctors were battling at the forefront, then the Clinical Research Organizations (CROs) have been working hard
Top 10 companies using CRISPR technologyARUNPANDIAN07
The revolutionary gene editing tool CRISPR/Cas9 has reached its height because of its accuracy and easy-to-design. Several gene corrections have been made by scientists in vitro and in vivo.
For more information, visit, www.theblackchalk.com
Katalyst Securities is a private equity/venture investment bank that specializes in growth capital and expansion stage investments in technology and healthcare. They source investment opportunities through a global network and partner with venture capital firms. Their goal is to identify innovative ideas, help bring them to life, create brands with long-term value, and drive successful results for portfolio companies and investors. They focus on transactions like private placements, alternative public offerings, and venture capital. Katalyst aims to achieve return on investment for entrepreneurs, high net worth individuals, family offices, and Swiss banks.
The New Orleans BioInnovation Center is a $48 million facility that partners with LSUHSC and Tulane to support the commercialization of biotechnologies in the region. It provides lab space, funding assistance, and business programming to 50 technology companies. Examples include NuMe Health, which is developing prebiotics for health conditions, and MiniVax, which received an NIH grant for vaccine development. The Center aims to continue growing the entrepreneurial culture and research base in the region while addressing challenges around workforce, capital, and retaining startup companies.
1) Evozyne uses evolution-based design and machine learning to engineer novel proteins to solve challenges in therapeutics and sustainability.
2) They have partnered with Takeda to develop an enzyme to treat a genetic disease, exceeding expectations, and are developing platforms for antibodies, gene editing, and gene optimization.
3) Evozyne aims to bring biology-based solutions to issues like carbon capture and untreated diseases by designing proteins with advanced functionality inspired by natural evolution.
Mc carter enabling innovation washu 11.7.14James McCarter
The Washington University Monsanto Graduate Fellows' Symposium on November 7th, 2014 fostered interaction between academia, industry, & entrepreneurship. Jim McCarter, Senior EIR at BioGenerator & Adjunct Professor of Genetics provided a quick tour of resources for start-ups at WashU & in St. Louis.
wyeth Download Documentation Credit Suisse Group Healthcare Conferencefinance12
This document is a presentation by Michael Kamarck from Wyeth discussing the company's manufacturing capabilities and strategies. It summarizes that Wyeth has a diversified business across pharmaceuticals, biotechnology, vaccines, and other areas. It has made over $3.5 billion in investments to support its biomanufacturing network and developed platform technologies to standardize processes. This allows production of multiple pipeline and commercial products using consistent materials and equipment. Wyeth has demonstrated the ability to increase yields and capacity for products like Enbrel and Prevnar through technological advances.
wyeth Credit Suisse Group Healthcare Conferencefinance12
This document provides an overview of Wyeth's business, including its diversification across scientific platforms, business platforms, and therapeutic approaches. It discusses Wyeth's core biotech/vaccine franchises that have high growth potential, such as Enbrel and Prevnar. The document also summarizes Wyeth's investments in biomanufacturing infrastructure and its leadership in biotech manufacturing and process development. Wyeth's standardized technology platforms are highlighted as helping to improve existing products and drive efficiencies.
The 10 most trusted vaccine solution providers, 2020Merry D'souza
In this edition, ‘The 10 Most Trusted Vaccine Solution Providers, 2020’ CIO Look has shortlisted various healthcare organizations which are playing an important role towards the global healthcare system.
This is a conference about drug discovery and drug development. G protein-coupled receptor (GPCR) and protein kinases are the biggest drug targets in medicine. Around half of all drugs, for whatever disease, work by interacting with different GPCRs and kinases.
Growing Stronger Research Fund Overview Jan 2012 For DonorsAmer Haider
Growing Stronger Research Fund aims to accelerate medical research to improve quality of life for people with Achondroplasia, the most common form of dwarfism. Their goal is to eliminate the need for multiple orthopedic surgeries by developing drug therapies. They are currently funding four research strategies, including blocking expression of the mutant gene or disabling the mutant protein. Their next steps are to raise $600,000 over three years to support additional lab testing and advance promising strategies toward clinical trials and approval.
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
The Southern California Consortium for Technology and Innovation in Pediatrics (CTIP) is one of seven FDA-funded pediatric device consortia working to develop medical devices for children. CTIP engages clinicians, engineers, entrepreneurs and others in developing pediatric technologies through events like Med-Innovation Rounds and symposiums. They provide support to 35 distinct pediatric device projects in their first year. To convince industry partners of opportunities in pediatrics, CTIP clearly defines projects' value propositions and market potential through due diligence. Their strategy pairs entrepreneurs with domain experts to advance technologies for children.
This document provides an overview of Kuwait Life Sciences Company (KLSC) and its subsidiaries which were established to stimulate the life sciences sector in the Middle East and North Africa region. KLSC is fully owned by NTEC, the technology transfer arm of the Kuwait Investment Authority. It has established five platform companies focused on pharmaceutical commercialization, medical devices, clinical research, healthcare training, and active pharmaceutical ingredients. The platforms work with world-class partners and have expanded operations across the MENA region since 2010. KLSC also invests in healthcare and life sciences funds and companies internationally.
The healthcare industry is being disrupted by technology and a shift to greater patient / individual empowerment. This represents a formidable opportunity for healthcare in Asia. What catalyst role could / should strategics play in Asia healthcare innovation and how?
The most advanced ivf and fertility centres 2018insightscare
With the need for high standards of IVF treatment, we bring the “The 10 Most Advanced IVF and Fertility Centers 2018.” These fertility clinics are providing contemporary paraphernalia to meet all the demands the IVF and Fertility vertical poses.
Biocat coordinates and promotes the biotechnology sector in Catalonia, focusing on adding value to research and consolidating biotechnology as an economic sector. BioWin is the health cluster of Wallonia that aims to foster innovation, human capital, infrastructure, and international promotion of SMEs. Euromediag stimulates synergy in the medical diagnostics sector in southern France through its network of over 70 partners from education, research, industry, healthcare, and government. LifeScience Klaster Krakow's medical diagnostics working group involves 27 organizations in research, services, and promotion related to molecular diagnostics, imaging, and biomarkers.
Similar to Osage University Partners Newsletter: December 2011 (20)
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
Discover innovative uses of Revit in urban planning and design, enhancing city landscapes with advanced architectural solutions. Understand how architectural firms are using Revit to transform how processes and outcomes within urban planning and design fields look. They are supplementing work and putting in value through speed and imagination that the architects and planners are placing into composing progressive urban areas that are not only colorful but also pragmatic.
4 Benefits of Partnering with an OnlyFans Agency for Content Creators.pdfonlyfansmanagedau
In the competitive world of content creation, standing out and maximising revenue on platforms like OnlyFans can be challenging. This is where partnering with an OnlyFans agency can make a significant difference. Here are five key benefits for content creators considering this option:
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...my Pandit
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
The Steadfast and Reliable Bull: Taurus Zodiac Signmy Pandit
Explore the steadfast and reliable nature of the Taurus Zodiac Sign. Discover the personality traits, key dates, and horoscope insights that define the determined and practical Taurus, and learn how their grounded nature makes them the anchor of the zodiac.
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
Profiles of Iconic Fashion Personalities.pdfTTop Threads
The fashion industry is dynamic and ever-changing, continuously sculpted by trailblazing visionaries who challenge norms and redefine beauty. This document delves into the profiles of some of the most iconic fashion personalities whose impact has left a lasting impression on the industry. From timeless designers to modern-day influencers, each individual has uniquely woven their thread into the rich fabric of fashion history, contributing to its ongoing evolution.
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...BBPMedia1
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
The Genesis of BriansClub.cm Famous Dark WEb PlatformSabaaSudozai
BriansClub.cm, a famous platform on the dark web, has become one of the most infamous carding marketplaces, specializing in the sale of stolen credit card data.
Cover Story - China's Investment Leader - Dr. Alyce SUmsthrill
In World Expo 2010 Shanghai – the most visited Expo in the World History
https://www.britannica.com/event/Expo-Shanghai-2010
China’s official organizer of the Expo, CCPIT (China Council for the Promotion of International Trade https://en.ccpit.org/) has chosen Dr. Alyce Su as the Cover Person with Cover Story, in the Expo’s official magazine distributed throughout the Expo, showcasing China’s New Generation of Leaders to the World.
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This presentation is a curated compilation of PowerPoint diagrams and templates designed to illustrate 20 different digital transformation frameworks and models. These frameworks are based on recent industry trends and best practices, ensuring that the content remains relevant and up-to-date.
Key highlights include Microsoft's Digital Transformation Framework, which focuses on driving innovation and efficiency, and McKinsey's Ten Guiding Principles, which provide strategic insights for successful digital transformation. Additionally, Forrester's framework emphasizes enhancing customer experiences and modernizing IT infrastructure, while IDC's MaturityScape helps assess and develop organizational digital maturity. MIT's framework explores cutting-edge strategies for achieving digital success.
These materials are perfect for enhancing your business or classroom presentations, offering visual aids to supplement your insights. Please note that while comprehensive, these slides are intended as supplementary resources and may not be complete for standalone instructional purposes.
Frameworks/Models included:
Microsoft’s Digital Transformation Framework
McKinsey’s Ten Guiding Principles of Digital Transformation
Forrester’s Digital Transformation Framework
IDC’s Digital Transformation MaturityScape
MIT’s Digital Transformation Framework
Gartner’s Digital Transformation Framework
Accenture’s Digital Strategy & Enterprise Frameworks
Deloitte’s Digital Industrial Transformation Framework
Capgemini’s Digital Transformation Framework
PwC’s Digital Transformation Framework
Cisco’s Digital Transformation Framework
Cognizant’s Digital Transformation Framework
DXC Technology’s Digital Transformation Framework
The BCG Strategy Palette
McKinsey’s Digital Transformation Framework
Digital Transformation Compass
Four Levels of Digital Maturity
Design Thinking Framework
Business Model Canvas
Customer Journey Map
Digital Transformation Frameworks: Driving Digital Excellence
Osage University Partners Newsletter: December 2011
1. 50 Monument Road
Bala Cynwyd, PA 19004
484.434.2255—T
484.434.2256—F
www.osagepartners.com
December 2011
Dear Colleagues and Friends,
Osage University Partners has had a busy and productive fall, closing on four new investments, with a
fifth in final diligence. In total, the Fund will have completed seven new investments in 2011, which
brings our portfolio to 16 companies. The pickup in investment pace is a welcomed surprise, and whether
this increased activity is a momentary blip or a sustainable pickup is unknown.
Over the past year, our sector diversification strategy has provided ballast for our Fund during a time
when both the life science and cleantech sectors faced significant headwinds. Life science venture firms
continue to shrink or disappear, leaving a reduced pool of capital available for early stage investments.
We have also seen sector rotation away from capital intense cleantech investments by some VC’s.
However, as noted in several recent blog posts, there have been positive trends in M&A and IPO activity,
and corporate investors across multiple sectors have become quite active.
Presently, we still expect 2012 to be a modest year in terms of financing activity, but we are encouraged
by the recent level of investment activity and remain cautiously optimistic.
New Investments
Our most recent investments are listed below and represent a wide breadth of industry sectors (healthcare
services, medical devices, diagnostics and therapeutics) and company development stages (Series A
through Series C).
• Clinipace Worldwide is a contract resource organization (CRO) that has developed a proprietary
on-demand software platform based on technology from the University of Florida to more
efficiently manage Phase I-IV clinical trials. Operating in seven countries, Clinipace serves small
and medium-sized biopharmaceutical and medical device companies, as well as academic
medical centers. The company’s Series C financing round was led by Morgan Stanley Venture
Partners, with participation from existing investor Hatteras Venture Partners. Osage participated
in this oversubscribed round through its partnership with the University of Florida.
• Tangent Medical is a development stage medical device company from the University of
Michigan that has designed a novel peripheral intravenous (PIV) access system to overcome
problems associated with conventional PIV fluid delivery systems. Through its partnership with
the University of Michigan, Osage invested in this highly sought-after Series A round alongside
lead investors Arboretum Ventures and Flagship Ventures.
• Sera Prognostics is developing a molecular diagnostic to assess the risk of preterm birth. The
company has licensed novel biomarkers from Brigham Young University and the University of
Utah. Sera Prognostics is led by the former President of Myriad Genetics, who during his tenure,
built Myriad’s revenues from $2 million to over $300 million. We invested in a heavily
oversubscribed Series A round alongside InterWest Partners, Domain Associates and Catalyst
Health Ventures.
• Cleave Biosciences is a Caltech spinoff that is developing novel oncology therapies by targeting
protein degradation pathways. The scientific founder is one of the world’s foremost experts on
protein degradation, and his last company was acquired in 2009 by Onyx Pharmaceuticals. Osage
2. invested in a tranched Series A financing round alongside US Venture Partners, 5AM, OrbiMed,
Clarus Ventures and Astellas Ventures.
Company Tracking
We continue to actively track the progress of your start-ups in order to identify potential financing
opportunities, and our internal database has grown accordingly over the past six months. We are now
actively following 1,088 start-ups, which we define as any company that has received third-party funding
or is likely to receive funding over the next 12 months (this number includes early, nascent technologies
as well).
Using these data, below is a sector distribution of the companies we are tracking in the Osage database.
The chart on the left shows the overall sector distribution of the companies in our database, while the
chart on the right shows a breakdown of bioscience companies into industry subsectors. Currently, 51%
of the Fund’s capital is invested in life science companies and 49% in physical science companies.
Sector
D
istribution
Bio
Subsectors
Osage Blog
We encourage you to continue reading and contributing to our blog at www.blogoup.com. The blog
provides commentary on investment and technology trends that are of interest to members of the
university innovation community. You might find several recent posts to be of interest, including
Pharma-Academic collaborations, a feature on rare diseases, and the academic drug discovery landscape.
2 Osage University Partners
3. Team
Recently, we have been focusing intensively on building out our team in order to provide deeper support
in the life sciences. In January, we will announce the hiring of a new Partner at Osage who will
spearhead our life science efforts. We think you will be pleased with the quality of our new partner on
many dimensions, including the quality of his investment experience, scientific pedigree and reputation in
the venture industry. We look forward to introducing you to our new Partner in early 2012.
We also strongly encourage communication, so please feel free to contact any of us with additional
company opportunities, questions, or suggestions.
Thank you for your continued support, and we wish you, and your offices, all the best in 2012.
Portfolio Companies
Company Description University Co-investors
Developing new molecular imaging agents Alta Partners, Eli Lilly
capable of identifying Alzheimer’s Disease Penn Ventures, Pfizer Ventures,
at its earliest stages Safeguard Scientifics
Cleave Biosciences is developing novel
5AM, USVP, OrbiMed, Clarus
therapeutics targeting the Ubiquitin- Caltech
Ventures, Astellas Ventures
Proteosome System (UPS)
A global digital clinical research organization Morgan Stanley Venture
U of Florida
(dCRO) Partners, Hatteras Ventures
Biopharmaceutical company dedicated to Quaker BioVentures, Domain
developing and commercializing novel Penn Associates, MedImmune
therapeutic Arginase inhibitors Ventures, NewSpring Capital
Developing and commercializing advanced Burrill & Company, Khosla
bio-fuels, the new generation of bio-based Caltech Ventures, Total Energy Fund,
fuels and chemicals Virgin Green Fund
The Column Group, Alta
Novel vaccine technologies for infectious and
Caltech Partners, Versant Ventures,
malignant diseases
ProQuest
Developing the next generation of receptor
Celtic Pharma, HBM
tyrosine kinase inhibitors for the treatment of Yale
BioCapital, Purdue Pharma
cancer
Unique technology platform to manufacture a
August Capital, Lux Capital,
new breed of monolithic opto-electronic Caltech
NEA, Sevin Rosen Funds
devices in a low cost CMOS process
Developing electronic circuits that can stretch Penn
up to 400% North Bridge Ventures
U of Illinois
Proprietary biomarkers that are predictive of BYU Domain Associates, InterWest,
preterm birth U of Utah Catalyst Ventures
Osage University Partners 3
4. DC to AC energy conversion devices for the Battery Ventures, Rho
U of Illinois
solar industry Ventures
NovaCath™ IV delivery system Michigan Arboretum Ventures, Flagship
Biogen IDEC, Clarus
Developing safer and more effective drugs for Ventures, MedImmune
Rockefeller
autoimmune and inflammatory diseases Ventures, Thomas McNerney
& Partners, Venrock
4 Osage University Partners
